Katexco is a second-generation pharmaceutical cannabis company targeting autoimmune diseases by a variety of approaches, including utilizing CBD or related compounds, or CB2 agonists. The company will be targeting multi-billion-dollar markets of multiple sclerosis, gastrointestinal disorders, gout, rheumatoid arthritis, osteoarthritis, and atherosclerosis, also involving new products.
Katexco was Founded by Prof Lawrence Steinman and Dr Jonathan Rothbard, who in Stanford developed over 26 medical research manuscripts together over the course of their careers and both of which have immense immunological therapy expertise. Prof Steinman’s research in his laboratory led to the development of the blockbuster drug Tysabri® (natalizumab), which is considered the most effective treatment for patients with multiple sclerosis and Crohn’s disease. Moreover, the company’s Co-Founder, Prof Sir Marc Feldmann, discovered one of the most important discoveries of modern science and medicine, anti-TNF therapy (the largest selling drug class globally) to treat inflammatory conditions such as arthritis, inflammatory bowel disease, and many more.
Katexco is leveraging their pioneering experience in immunology to research and create orally active and available anti-inflammatory medicines.
The market for treating gastrointestinal disorders was worth $59.98B USD in 2018, and is expected to rise to $92.25B USD in 2025 at a CAGR of 6.6%.
The market for treating multiple sclerosis was worth $22.85B USD in 2018, and is expected to rise to $27.38B USD at a CAGR of 6.3%.
The market for treating gout was worth $2.8B USD in 2018, and is expected to rise to $7.9B USD in 2025 at a CAGR of 16%.